Xenios
126 employees on LinkedIn · 1 known investors
Xenios develops extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) technologies for patients with cardiac and/or pulmonary failure. The company provides integrated solutions that combine cardiac and pulmonary support on a single platform for critical care physicians.
Investors · 1
Frequently asked questions
- What does Xenios do?
- Xenios develops extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) technologies for patients with cardiac and/or pulmonary failure. The company provides integrated solutions that combine cardiac and pulmonary support on a single platform for critical care physicians.
- Who are Xenios's investors?
- Xenios's investors include D11Z.